ARGNF
Price
$683.14
Change
+$63.70 (+10.28%)
Updated
Aug 25 closing price
Capitalization
43.46B
SLS
Price
$1.78
Change
-$0.05 (-2.73%)
Updated
Sep 3, 04:59 PM (EDT)
Capitalization
192.69M
70 days until earnings call
Interact to see
Advertisement

ARGNF vs SLS

Header iconARGNF vs SLS Comparison
Open Charts ARGNF vs SLSBanner chart's image
Argen X
Price$683.14
Change+$63.70 (+10.28%)
Volume$4
Capitalization43.46B
SELLAS Life Sciences Group
Price$1.78
Change-$0.05 (-2.73%)
Volume$114.67K
Capitalization192.69M
ARGNF vs SLS Comparison Chart in %
Loading...
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGNF vs. SLS commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGNF is a Buy and SLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (ARGNF: $683.14 vs. SLS: $1.83)
Brand notoriety: ARGNF and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGNF: 53% vs. SLS: 81%
Market capitalization -- ARGNF: $43.46B vs. SLS: $187.43M
ARGNF [@Biotechnology] is valued at $43.46B. SLS’s [@Biotechnology] market capitalization is $187.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGNF’s FA Score shows that 1 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • ARGNF’s FA Score: 1 green, 4 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARGNF is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARGNF’s TA Score shows that 2 TA indicator(s) are bullish while SLS’s TA Score has 6 bullish TA indicator(s).

  • ARGNF’s TA Score: 2 bullish, 2 bearish.
  • SLS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SLS is a better buy in the short-term than ARGNF.

Price Growth

ARGNF (@Biotechnology) experienced а 0.00% price change this week, while SLS (@Biotechnology) price change was +0.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

SLS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGNF($43.5B) has a higher market cap than SLS($193M). SLS YTD gains are higher at: 75.962 vs. ARGNF (4.720). ARGNF has higher annual earnings (EBITDA): 690M vs. SLS (-27.18M). ARGNF has more cash in the bank: 3.93B vs. SLS (25.3M). SLS has less debt than ARGNF: SLS (737K) vs ARGNF (43.2M). ARGNF has higher revenues than SLS: ARGNF (3.05B) vs SLS (0).
ARGNFSLSARGNF / SLS
Capitalization43.5B193M22,539%
EBITDA690M-27.18M-2,538%
Gain YTD4.72075.9626%
P/E Ratio34.77N/A-
Revenue3.05B0-
Total Cash3.93B25.3M15,526%
Total Debt43.2M737K5,862%
FUNDAMENTALS RATINGS
ARGNF vs SLS: Fundamental Ratings
ARGNF
SLS
OUTLOOK RATING
1..100
4419
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
38100
PRICE GROWTH RATING
1..100
4240
P/E GROWTH RATING
1..100
89100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLS's Valuation (55) in the Biotechnology industry is in the same range as ARGNF (72) in the null industry. This means that SLS’s stock grew similarly to ARGNF’s over the last 12 months.

ARGNF's Profit vs Risk Rating (13) in the null industry is significantly better than the same rating for SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew significantly faster than SLS’s over the last 12 months.

ARGNF's SMR Rating (38) in the null industry is somewhat better than the same rating for SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew somewhat faster than SLS’s over the last 12 months.

SLS's Price Growth Rating (40) in the Biotechnology industry is in the same range as ARGNF (42) in the null industry. This means that SLS’s stock grew similarly to ARGNF’s over the last 12 months.

ARGNF's P/E Growth Rating (89) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARGNFSLS
RSI
ODDS (%)
Bearish Trend 2 days ago
23%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
29%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
30%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
28%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
N/A
Bullish Trend 17 days ago
86%
Declines
ODDS (%)
N/A
Bearish Trend 24 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARGNF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ERII14.340.13
+0.91%
Energy Recovery
HPE22.680.11
+0.49%
Hewlett Packard Enterprise Company
CRGO3.290.01
+0.30%
Freightos Limited
PLBL9.95-0.04
-0.40%
Polibeli Group Ltd
COOT0.55-0.05
-8.14%
Australian Oilseeds Holdings Limited

ARGNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with SLS. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGNF
1D Price
Change %
ARGNF100%
N/A
SLS - ARGNF
36%
Loosely correlated
-4.69%
RLMD - ARGNF
31%
Poorly correlated
+26.79%
TPST - ARGNF
27%
Poorly correlated
+2.52%
GNNSF - ARGNF
23%
Poorly correlated
N/A
CVALF - ARGNF
23%
Poorly correlated
+1.16%
More

SLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with AKRO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-4.69%
AKRO - SLS
42%
Loosely correlated
-2.76%
ARGNF - SLS
36%
Loosely correlated
N/A
SABS - SLS
28%
Poorly correlated
+1.92%
ETNB - SLS
25%
Poorly correlated
+1.77%
TECX - SLS
25%
Poorly correlated
-34.81%
More